AMIX

Business Context and Reporting Period

Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended September 30, 2024
Business Overview: A pre-revenue, clinical-stage medical device company developing technologies for sensing and treating disorders of the peripheral nervous system, initially focusing on pain management for pancreatic cancer.
Corporate Status: Smaller reporting company and emerging growth company. Completed a 1-for-20 reverse stock split effective October 24, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by 16% ($1.1 million) year-over-year for the six-month period. This reduction is primarily due to the absence of a $4.6 million non-cash warrant expense related to a termination agreement recorded in the prior year.
• Expense Composition: Despite the total decrease, core operational costs rose significantly. General and Administrative (G&A) expenses increased 167% ($2.2 million) and Research and Development (R&D) expenses increased 154% ($1.3 million) compared to the prior six months, driven by expanded management teams, stock-based compensation, and clinical trial costs.
• Liquidity: Cash balances decreased by $3.5 million during the six months ended September 30, 2024, due to net cash used in operating activities of $3.4 million. No financing activities occurred in the current period, whereas the prior period included $3.1 million in financing proceeds.
• Debt: Convertible notes payable increased slightly in net carrying value due to amortization of debt discounts. Principal amount remains at $1.33 million.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management estimates current cash resources are sufficient to fund operations only into the second calendar quarter of 2025. The filing explicitly states that these factors raise substantial doubt about the Company's ability to continue as a going concern within one year. Additional capital of approximately $40 million is estimated to be required to reach commercialization.
• Capital Raising: The Company must raise additional capital to continue operations and obtain regulatory clearance. There is no assurance that financing will be available on acceptable terms.
• Reverse Stock Split: A 1-for-20 reverse stock split was effected on October 24, 2024, to regain Nasdaq compliance. The Company is currently investigating a request from the DTCC to issue 271,846 shares for fractional share rounding, which could result in dilution or liability if not resolved.
• Internal Controls: The Company disclosed material weaknesses in internal control over financial reporting, citing a lack of segregation of duties and limited staffing. Management has hired new personnel and consultants to address these issues.
• Recent Agreements: Entered into a license agreement with RF Innovations, Inc. for ablation technology, issuing 12,500 shares of common stock as consideration.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" regarding going concern status and the Q2 2025 liquidity horizon.
• Reverse Stock Split Impact: Monitor the resolution of the DTCC inquiry regarding the issuance of 271,846 shares for fractional rounding and its potential dilutive effect.
• Internal Controls: Review future filings for progress in remediating material weaknesses in financial reporting controls.
• Debt Conversion: Track the status of the $1.33 million convertible notes and the 4.99% beneficial ownership limitation that prevented full conversion at the IPO.
• Expense Trajectory: Assess the sustainability of the 150%+ year-over-year increase in core G&A and R&D expenses in the absence of revenue.